Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

bioAffinity Technologies (BIAF) Interest & Investment Income (2021 - 2026)

bioAffinity Technologies has reported Interest & Investment Income over the past 5 years, most recently at $10026.0 for Q1 2026.

  • Quarterly Interest & Investment Income rose 1749.82% to $10026.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $32869.0 through Mar 2026, up 173.34% year-over-year, with the annual reading at $23385.0 for FY2025, 32.79% up from the prior year.
  • Interest & Investment Income was $10026.0 for Q1 2026 at bioAffinity Technologies, down from $19730.0 in the prior quarter.
  • Over five years, Interest & Investment Income peaked at $44124.0 in Q2 2023 and troughed at $276.0 in Q2 2022.
  • The 5-year median for Interest & Investment Income is $6770.5 (2022), against an average of $13705.6.
  • Year-over-year, Interest & Investment Income skyrocketed 15886.96% in 2023 and then crashed 91.81% in 2024.
  • A 5-year view of Interest & Investment Income shows it stood at $38447.0 in 2022, then crashed by 68.37% to $12160.0 in 2023, then crashed by 66.54% to $4069.0 in 2024, then soared by 384.89% to $19730.0 in 2025, then plummeted by 49.18% to $10026.0 in 2026.
  • Per Business Quant, the three most recent readings for BIAF's Interest & Investment Income are $10026.0 (Q1 2026), $19730.0 (Q4 2025), and $1088.0 (Q3 2025).